- New tablet formulation of risvodetinib
approximately doubles drug exposure at same dose –
- Tablet formulation to be evaluated in the
planned 12-month extension portion of the 201 trial–
BOSTON and ATLANTA, Aug. 24,
2023 /PRNewswire/ -- Inhibikase Therapeutics,
Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage
pharmaceutical company developing protein kinase inhibitor
therapeutics to modify the course of Parkinson's disease ("PD"),
Parkinson's-related disorders and other diseases of the Abelson
Tyrosine Kinases, today announced that it has developed a novel
tablet formulation of IkT-148009, designed to improve drug exposure
and overcome existing challenges related to patient use.
"As we advance our 201 trial evaluating risvodetinib at 50, 100
and 200 mg to treat Parkinson's disease, we have continued to
expand our formulation and delivery capabilities," commented Dr.
Milton Werner, President & CEO
of Inhibikase. "We recently completed characterization of a novel
tablet formulation that mimics the oral formulation we used to
evaluate efficacy in validated animal models of Parkinson's
disease. This novel tablet formulation nearly doubles drug exposure
at steady-state for the same dose of risvodetinib, potentially
enabling us to use a lower dose to reach therapeutic
efficacy. This could improve the overall safety and
tolerability of risvodetinib. In addition, the smaller size of
these tablets compared to the capsules currently in use in
the 201 clinical trial, the smaller tablets may overcome challenges
patients have swallowing oral medication as a result of their
disease. This new tablet formulation would be implemented in the
planned 12 month extension of the 201 trial."
About Inhibikase
(www.inhibikase.com)
Inhibikase
Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical
company developing therapeutics for Parkinson's disease and related
disorders. Inhibikase's multi-therapeutic pipeline has a primary
focus on neurodegeneration and its lead program IkT-148009, an
Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of
Parkinson's disease inside and outside the brain as well as other
diseases that arise from Ableson Tyrosine Kinases. Its
multi-therapeutic pipeline is pursuing Parkinson's-related
disorders of the brain and GI tract, orphan indications related to
Parkinson's disease such as Multiple System Atrophy, and drug
delivery technologies for kinase inhibitors such as IkT-001Pro, a
prodrug of the anticancer agent imatinib mesylate that the Company
believes will provide a better patient experience with fewer
on-dosing side-effects. The Company's RAMP™ medicinal chemistry
program has identified a number of follow-on compounds to
IkT-148009 to be potentially applied to other cognitive and motor
function diseases of the brain. Inhibikase is headquartered in
Atlanta, Georgia with an office in
Lexington, Massachusetts.
Social Media Disclaimer
Investors and others should
note that we announce material financial information to our
investors using our investor relations website, press releases, SEC
filings and public conference calls and webcasts. The Company
intends to also
use Twitter, Facebook, LinkedIn and YouTube as
a means of disclosing information about the Company, its services
and other matters and for complying with its disclosure obligations
under Regulation FD.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
terminology such as "believes," "expects," "may," "will," "should,"
"anticipates," "plans," or similar expressions or the negative of
these terms and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based on Inhibikase's current expectations and assumptions. Such
statements are subject to certain risks and uncertainties, which
could cause Inhibikase's actual results to differ materially from
those anticipated by the forward-looking statements. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include our ability to
successfully conduct clinical trials and that results in our animal
studies may not be replicated in humans, as well as such other
factors that are included in our periodic reports on Form 10-K and
Form 10-Q that we file with the U.S. Securities and Exchange
Commission. Any forward-looking statement in this release speaks
only as of the date of this release. Inhibikase undertakes no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by any
applicable securities laws.
Contacts:
Company Contact:
Milton H.
Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex
Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-announces-development-of-novel-formulation-of-risvodetinib-301905580.html
SOURCE Inhibikase Therapeutics, Inc.